Secukinumab re‐initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis
Gespeichert in:
| Veröffentlicht in: | British journal of dermatology (1951) 2017-09, Vol.177 (3), p.879-881 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 881 |
|---|---|
| container_issue | 3 |
| container_start_page | 879 |
| container_title | British journal of dermatology (1951) |
| container_volume | 177 |
| creator | Blauvelt, A. Reich, K. Warren, R.B. Szepietowski, J.C. Sigurgeirsson, B. Tyring, S. K. Messina, I. Bhosekar, V. Oliver, J. Papavassilis, C. Frueh, J. Langley, R.G.B. |
| description | |
| doi_str_mv | 10.1111/bjd.15656 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1899103753</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1941246796</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3536-72df03b936687c884a2b02898b343ccbeaf64a57cec8e51050e2824699133d8d3</originalsourceid><addsrcrecordid>eNp1kc1u1TAQha0KRG8vLPoCyFI37SKtHceOs2zLvyqxANaW40x6fZvEqe206o43gGfkSRi4hQUS3oxG55uj8RxCDjk75fjO2m13yqWSao-suFCyKLkQT8iKMVYXrFFinxyktGWMCybZM7Jf6qrRklcr8u0TuOXGT8toWxrhx9fvfvLZ2-zDRK3beLiDhMK19RMNPd346w22aQ5TAjqgOiSK0owTMOVE7zcB-wwxLnOmOYLNIwq0D5GOoYNoM9AcaMLRCHQe7O2CJYXobfLpOXna2yHBi8e6Jl_evP58-a64-vj2_eX5VeGEFKqoy65nom2EUrp2Wle2bFmpG92KSjjXgu1VZWXtwGmQHH8NpS4r1TR4mU53Yk2Od75zDLhAymb0ycEw2AnCkgzXiDJRS4Ho0T_oNixxwu0MbyqOrjWeeE1OdpSLIaUIvZmjH218MJyZXykZTMn8TgnZl4-OSztC95f8EwsCZzvg3g_w8H8nc_Hh1c7yJ6SvnsY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1941246796</pqid></control><display><type>article</type><title>Secukinumab re‐initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Blauvelt, A. ; Reich, K. ; Warren, R.B. ; Szepietowski, J.C. ; Sigurgeirsson, B. ; Tyring, S. K. ; Messina, I. ; Bhosekar, V. ; Oliver, J. ; Papavassilis, C. ; Frueh, J. ; Langley, R.G.B.</creator><creatorcontrib>Blauvelt, A. ; Reich, K. ; Warren, R.B. ; Szepietowski, J.C. ; Sigurgeirsson, B. ; Tyring, S. K. ; Messina, I. ; Bhosekar, V. ; Oliver, J. ; Papavassilis, C. ; Frueh, J. ; Langley, R.G.B.</creatorcontrib><identifier>ISSN: 0007-0963</identifier><identifier>EISSN: 1365-2133</identifier><identifier>DOI: 10.1111/bjd.15656</identifier><identifier>PMID: 28498514</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Antibodies, Monoclonal - therapeutic use ; Biological Products - therapeutic use ; Dermatologic Agents - therapeutic use ; Double-Blind Method ; Drug Substitution ; Female ; Humans ; Male ; Middle Aged ; Monoclonal antibodies ; Psoriasis ; Psoriasis - drug therapy ; Recurrence ; Treatment Outcome</subject><ispartof>British journal of dermatology (1951), 2017-09, Vol.177 (3), p.879-881</ispartof><rights>2017 British Association of Dermatologists</rights><rights>Copyright © 2017 British Association of Dermatologists</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3536-72df03b936687c884a2b02898b343ccbeaf64a57cec8e51050e2824699133d8d3</citedby><cites>FETCH-LOGICAL-c3536-72df03b936687c884a2b02898b343ccbeaf64a57cec8e51050e2824699133d8d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjd.15656$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjd.15656$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27933,27934,45583,45584</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28498514$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Blauvelt, A.</creatorcontrib><creatorcontrib>Reich, K.</creatorcontrib><creatorcontrib>Warren, R.B.</creatorcontrib><creatorcontrib>Szepietowski, J.C.</creatorcontrib><creatorcontrib>Sigurgeirsson, B.</creatorcontrib><creatorcontrib>Tyring, S. K.</creatorcontrib><creatorcontrib>Messina, I.</creatorcontrib><creatorcontrib>Bhosekar, V.</creatorcontrib><creatorcontrib>Oliver, J.</creatorcontrib><creatorcontrib>Papavassilis, C.</creatorcontrib><creatorcontrib>Frueh, J.</creatorcontrib><creatorcontrib>Langley, R.G.B.</creatorcontrib><title>Secukinumab re‐initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis</title><title>British journal of dermatology (1951)</title><addtitle>Br J Dermatol</addtitle><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Biological Products - therapeutic use</subject><subject>Dermatologic Agents - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Drug Substitution</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Psoriasis</subject><subject>Psoriasis - drug therapy</subject><subject>Recurrence</subject><subject>Treatment Outcome</subject><issn>0007-0963</issn><issn>1365-2133</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1u1TAQha0KRG8vLPoCyFI37SKtHceOs2zLvyqxANaW40x6fZvEqe206o43gGfkSRi4hQUS3oxG55uj8RxCDjk75fjO2m13yqWSao-suFCyKLkQT8iKMVYXrFFinxyktGWMCybZM7Jf6qrRklcr8u0TuOXGT8toWxrhx9fvfvLZ2-zDRK3beLiDhMK19RMNPd346w22aQ5TAjqgOiSK0owTMOVE7zcB-wwxLnOmOYLNIwq0D5GOoYNoM9AcaMLRCHQe7O2CJYXobfLpOXna2yHBi8e6Jl_evP58-a64-vj2_eX5VeGEFKqoy65nom2EUrp2Wle2bFmpG92KSjjXgu1VZWXtwGmQHH8NpS4r1TR4mU53Yk2Od75zDLhAymb0ycEw2AnCkgzXiDJRS4Ho0T_oNixxwu0MbyqOrjWeeE1OdpSLIaUIvZmjH218MJyZXykZTMn8TgnZl4-OSztC95f8EwsCZzvg3g_w8H8nc_Hh1c7yJ6SvnsY</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Blauvelt, A.</creator><creator>Reich, K.</creator><creator>Warren, R.B.</creator><creator>Szepietowski, J.C.</creator><creator>Sigurgeirsson, B.</creator><creator>Tyring, S. K.</creator><creator>Messina, I.</creator><creator>Bhosekar, V.</creator><creator>Oliver, J.</creator><creator>Papavassilis, C.</creator><creator>Frueh, J.</creator><creator>Langley, R.G.B.</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>201709</creationdate><title>Secukinumab re‐initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis</title><author>Blauvelt, A. ; Reich, K. ; Warren, R.B. ; Szepietowski, J.C. ; Sigurgeirsson, B. ; Tyring, S. K. ; Messina, I. ; Bhosekar, V. ; Oliver, J. ; Papavassilis, C. ; Frueh, J. ; Langley, R.G.B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3536-72df03b936687c884a2b02898b343ccbeaf64a57cec8e51050e2824699133d8d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Biological Products - therapeutic use</topic><topic>Dermatologic Agents - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Drug Substitution</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Psoriasis</topic><topic>Psoriasis - drug therapy</topic><topic>Recurrence</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Blauvelt, A.</creatorcontrib><creatorcontrib>Reich, K.</creatorcontrib><creatorcontrib>Warren, R.B.</creatorcontrib><creatorcontrib>Szepietowski, J.C.</creatorcontrib><creatorcontrib>Sigurgeirsson, B.</creatorcontrib><creatorcontrib>Tyring, S. K.</creatorcontrib><creatorcontrib>Messina, I.</creatorcontrib><creatorcontrib>Bhosekar, V.</creatorcontrib><creatorcontrib>Oliver, J.</creatorcontrib><creatorcontrib>Papavassilis, C.</creatorcontrib><creatorcontrib>Frueh, J.</creatorcontrib><creatorcontrib>Langley, R.G.B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of dermatology (1951)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Blauvelt, A.</au><au>Reich, K.</au><au>Warren, R.B.</au><au>Szepietowski, J.C.</au><au>Sigurgeirsson, B.</au><au>Tyring, S. K.</au><au>Messina, I.</au><au>Bhosekar, V.</au><au>Oliver, J.</au><au>Papavassilis, C.</au><au>Frueh, J.</au><au>Langley, R.G.B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Secukinumab re‐initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis</atitle><jtitle>British journal of dermatology (1951)</jtitle><addtitle>Br J Dermatol</addtitle><date>2017-09</date><risdate>2017</risdate><volume>177</volume><issue>3</issue><spage>879</spage><epage>881</epage><pages>879-881</pages><issn>0007-0963</issn><eissn>1365-2133</eissn><cop>England</cop><pub>Oxford University Press</pub><pmid>28498514</pmid><doi>10.1111/bjd.15656</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0963 |
| ispartof | British journal of dermatology (1951), 2017-09, Vol.177 (3), p.879-881 |
| issn | 0007-0963 1365-2133 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1899103753 |
| source | MEDLINE; Access via Wiley Online Library; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Antibodies, Monoclonal - therapeutic use Biological Products - therapeutic use Dermatologic Agents - therapeutic use Double-Blind Method Drug Substitution Female Humans Male Middle Aged Monoclonal antibodies Psoriasis Psoriasis - drug therapy Recurrence Treatment Outcome |
| title | Secukinumab re‐initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T13%3A06%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Secukinumab%20re%E2%80%90initiation%20achieves%20regain%20of%20high%20response%20levels%20in%20patients%20who%20interrupt%20treatment%20for%20moderate%20to%20severe%20plaque%20psoriasis&rft.jtitle=British%20journal%20of%20dermatology%20(1951)&rft.au=Blauvelt,%20A.&rft.date=2017-09&rft.volume=177&rft.issue=3&rft.spage=879&rft.epage=881&rft.pages=879-881&rft.issn=0007-0963&rft.eissn=1365-2133&rft_id=info:doi/10.1111/bjd.15656&rft_dat=%3Cproquest_cross%3E1941246796%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1941246796&rft_id=info:pmid/28498514&rfr_iscdi=true |